Rebecca Frey joined Cardurion as chief operating officer in March 2018. As a member of Cardurion’s leadership team Rebecca is accountable for all aspects of operations, including drug development and manufacturing, across the portfolio. Rebecca is a versatile biopharmaceutical leader with significant experience in development, manufacturing and commercialization spanning a wide range of therapeutic areas and product platforms.
She most recently served as executive vice president of operations at Prevail Therapeutics, where she led clinical operations and early development planning for a gene therapy portfolio. Prior to that, Rebecca spent eleven years in rare disease development and operations at Alexion Pharmaceuticals.
During her tenure, Rebecca held a wide range of leadership roles in development, project management and manufacturing, including vice president of global operations, board liaison, head of project management and chief of staff to the CEO.
Prior to Alexion, Rebecca spent six years in clinical operations and medical affairs at Novartis Pharmaceuticals. Rebecca earned her Doctor of Pharmacy from Northeastern University and completed her post-doctoral clinical research fellowship at Northeastern University and Tufts Medical Center.
She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management and she a 2017 graduate of the Women in Bio Boardroom Ready program. Rebecca is also a member of the Dean’s Advisory Board for the University of Connecticut School of Pharmacy.